Quality and efficiency of statin prescribing across countries with a special focus on South Africa; findings and future implications

References

• Godman B, Shrank W, Andersen M, et al. Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications. Exp Rev Pharmacoecon Outcomes Res 2010;10(6):707-22
   PubMed Web of Science ®Google Scholar
• Raal F SC, Patel J, Becker P. A multicentre, open-label, observational study to evaluate the low-density lipoprotein cholesterol-lowering effect of ezetimibe as prescribed in daily routine practice in the South African population. Cardiovasc J Afr 2007;16(5):325-9
   Google Scholar
• Klug EQ, Raal AM FJ, Taskinen M-R, et al. South African Dyslipidaemia Guideline Consensus Statement - A joint statement from the South African Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA). JEMDSA 2012;17(3):155-65
   Google Scholar
• Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366(9493):1267-78
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Kjekshus J, Berg K, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 2004;5(3):81-7
   PubMed Web of Science ®Google Scholar
• Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371(9607):117-25
   PubMed Web of Science ®Google Scholar
• Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007;28(19):2375-414
   PubMed Web of Science ®Google Scholar
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361(9374):2005-16
   PubMed Web of Science ®Google Scholar
• Ryden L, Standl E, Bartnik M, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007;28(1):88-136
   PubMed Web of Science ®Google Scholar
• SIGN. Heart disease – quick reference guide. Available from: http://www.sign.ac.uk/pdf/qrgchd.pdf2007
   Google Scholar
• SIGN. Management of diabetes. Available from: http://www.sign.ac.uk/pdf/qrg116.pdf 2010
   Google Scholar
• Walley T, Folino-Gallo P, Schwabe U, van Ganse E. Variations and increase in use of statins across Europe: data from administrative databases. BMJ (Clinical research ed) 2004;328(7436):385-6
   PubMedGoogle Scholar
• Weng TC, Yang YH, Lin SJ, Tai SH. A systematic review and meta-analysis on the therapeutic equivalence of statins. J Clin Pharm Ther 2010;35(2):139-51
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005;294(19):2437-45
   PubMed Web of Science ®Google Scholar
• Usher-Smith J, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on. Int J Clin Pract 2008;62(3):480-4
   PubMed Web of Science ®Google Scholar
• Sakshaug S, Furu K, Karlstad O, et al. Switching statins in Norway after new reimbursement policy: a nationwide prescription study. Br J Clin Pharmacol 2007;64(4):476-81
   PubMed Web of Science ®Google Scholar
• Godman B, Schwabe U, Selke G, Wettermark B. Update of recent reforms in Germany to enhance the quality and efficiency of prescribing of proton pump inhibitors and lipid-lowering drugs. Pharmacoeconomics 2009;27(5):435-8
   PubMed Web of Science ®Google Scholar
• Martikainen JE, Saastamoinen LK, Korhonen MJ, et al. Impact of restricted reimbursement on the use of statins in Finland: a register-based study. Med Care 2010;48(9):761-6
   PubMed Web of Science ®Google Scholar
• Bennie M, Godman B, Bishop I, Campbell S. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland. Expert Rev Pharmacoecon Outcomes Res 2012;12(1):125-30
   PubMed Web of Science ®Google Scholar
• Woerkom M, Piepenbrink H, Godman B, et al. Ongoing measures to enhance the efficiency of prescribing of proton pump inhibitors and statins in The Netherlands: influence and future implications. J Comp Eff Res 2012;1(6):527-38
   PubMed Web of Science ®Google Scholar
• Godman B, Wettermark B, Hoffmann M, et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevance. Expert Rev Pharmacoecon Outcomes Res 2009;9(1):65-83
   PubMedGoogle Scholar
• McGinn D, Godman B, Lonsdale J, et al. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications. Expert Rev Pharmacoecon Outcomes Res 2010;10(1):73-85
   PubMed Web of Science ®Google Scholar
• Godman B, Malmström R, Bennie M, Sakshaug S, et al. Prescribing restrictions - a necessary strategy among some European countries to enhance future prescribing efficiency?’ Reviews in Health Care 2012;3(1):5-16
   Google Scholar
• Pettersson B, Hoffmann M, Wandell P, Levin LA. Utilization and costs of lipid modifying therapies following health technology assessment for the new reimbursement scheme in Sweden. Health policy 2012;104(1):84-91
   PubMedGoogle Scholar
• Pichetti S, Sermet C, Godman B, et al. Multilevel analysis of the influence of patients’ and general practitioners’ characteristics on patented versus multiple-sourced statin prescribing in France. Appl Health Econ Health Policy 2013;11(3):205-18
   PubMedGoogle Scholar
• Kiviniemi V, Peura P, Helin-Salmivaara A, et al. Suboptimal use of statins at treatment initiation. Eur J Clin Pharmacol 2011;67(9):971-3
   PubMed Web of Science ®Google Scholar
• Feely J, Bennett K. Epidemiology and economics of statin use. Ir Med J 2008;101(6):188-91
   PubMedGoogle Scholar
• Mantel-Teeuwisse AK, Klungel OH, Schalekamp T, et al. Suboptimal choices and dosing of statins at start of therapy. Br J Clin Pharmacol 2005;60(1):83-9
   PubMed Web of Science ®Google Scholar
• Hartz I, Sakshaug S, Furu K, et al. Aspects of statin prescribing in Norwegian counties with high, average and low statin consumption – an individual-level prescription database study. BMC Clin Pharmacol 2007;7:14
   PubMedGoogle Scholar
• SIGN. Heart disease. 2007, updated 2012. Available from: www.sign.ac.uk/pdf/qrgchd.pdf
   Google Scholar
• Raal F SC, Blom D, Marx J, et al. A South African survey on the under-treatment of hypercholesterolaemia. Cardiovasc J Afr 2011;22(5):1-7
   Google Scholar
• Opie LH, Dalby AJ. Cardiovascular prevention: lifestyle and statins–competitors or companions? S Afr Med J 2014;104(3):168-73
   PubMedGoogle Scholar
• PSSA Pharmacy Law Compendium. Medicines and Related Substances Act (Act 101 of 1965). Lexis Nexis, Durban, 2011;1(9)
   Google Scholar
• Pharasi B, Miot J. Medicines Selection and Procurement in South Africa. S Afr Health Rev 2013;117-85
   Google Scholar
• Truter I. Prescribed Daily Doses (PDDs) of Hypolipidaemic Agents in South Africa with Emphasis on HMG CoA Reductase Inhibitors. J Health Sci 2014;4(1):11-17
   Google Scholar
• Godman B, Bennie M, Campbell S, Wettermark B, Truter I. Different initiatives across countries to enhance the prescribing of generic PPIs; findings and implications. Basic Clin Pharmacol Toxicol 2014;115(Suppl 1):66
   Google Scholar
• Blazing MA, Giugliano RP, Cannon CP, et al. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population. Am Heart J 2014;168(2):205-12.e1
   PubMedGoogle Scholar
• Green D, Panayotova R, Ritchie JP, et al. Lipid-lowering therapy in chronic kidney disease: is there a role for ezetimibe? J Ren Care 2012;38(3):138-46
   PubMedGoogle Scholar
• Lu L, Krumholz HM, Tu JV, et al. Impact of the ENHANCE trial on the use of ezetimibe in the United States and Canada. Am Heart J 2014;167(5):683-9
   PubMedGoogle Scholar
• Rizzo M, Battista Rini G. Ezetimibe, cardiovascular risk and atherogenic dyslipidaemia. Arch Medical Sci 2011;7(1):5-7
   PubMedGoogle Scholar
• Suckling K. The ENHANCE Study: an unusual publication of trial data raises questions beyond ezetimibe. Expert Opin Pharmacother 2008;9(7):1067-70
   PubMed Web of Science ®Google Scholar
• WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2011. WHO, Oslo. 2013. Available from: www.whocc.no/atc_ddd_index/
   Google Scholar
• WHO. Introduction to Drug Utilisation Research. WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological Services. ISBN 92 4 156234 X (NLM classification: WB 330). Available from: www.who.int/medicines/areas/quality_safety/safety_efficacy/Drug%20utilization%20research.pdf2003
   Google Scholar
• Truter I, Kotze TJ. A drug utilisation study investigating prescribed daily doses of hypolipidaemic agents. S Afr Med J 1996;86(11):1397-401
   PubMedGoogle Scholar
• Goldenberg I, Benderly M, Goldbourt U. Update on the use of fibrates: focus on bezafibrate. Vasc Health Risk Manag 2008;4(1):131-41
   PubMedGoogle Scholar
• Day C, Gray A. Health and Related Indicators. S Afr Health Rev 2013;208-322
   Google Scholar
• Doran T, Fullwood C, Gravelle H, et al. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med 2006;355(4):375-84
   PubMed Web of Science ®Google Scholar
• Godman B, Shrank W, Andersen M, et al. Policies to enhance prescribing efficiency in europe: findings and future implications. Front Pharmacol 2010;1:141
   PubMed Web of Science ®Google Scholar
• Garuoliene K, Godman B, Gulbinovic J, et al. European countries with small populations can obtain low prices for drugs: Lithuania as a case history. Exp Rev Pharmacoecon Outcomes Res 2011;11(3):343-9
   PubMed Web of Science ®Google Scholar
• Markovic-Pekovic V, Skrbic R, Godman B, Gustafsson LL. Ongoing initiatives in the Republic of Srpska to enhance prescribing efficiency: influence and future directions. Exp Rev Pharmacoecon Outcomes Res 2012;12(5):661-71
   PubMed Web of Science ®Google Scholar
• Sermet C, Andrieu V, Godman B, et al. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy 2010;8(1):7-24
   PubMedGoogle Scholar
• Godman B, Sakshaug S, Berg C, et al. Combination of prescribing restrictions and policies to engineer low prices to reduce reimbursement costs. Exp Rev Pharmacoecon Outcomes Res 2011;11(1):121-9
   PubMed Web of Science ®Google Scholar
• Godman B, Bucsics A, Burkhardt T, et al. Insight into recent reforms and initiatives in Austria: implications for key stakeholders. Exp Rev Pharmacoecon Outcomes Res 2008;8(4):357-71
   PubMedGoogle Scholar
• Godman B, Bennie M, Baumgärtel C, Sović Brkičić L, et al. Essential to increase the use of generics in Europe to maintain comprehensive healthcare? Farmeconomia: Health Economics and Therapeutic Pathways 2012;13(Suppl 3):5-20
   Google Scholar
• Godman B, Abuelkhair M, Vitry A, Abdu S, et al. Payers endorse generics to enhance prescribing efficiency; impact and future implications, a case history approach. GaBI 2012;1(2):21-35
   Google Scholar
• Olsson E, Kalvemark Sporrong S. Pharmacists’ experiences and attitudes regarding generic drugs and generic substitution: two sides of the coin. Int J Pharm Pract 2012;20(6):377-83
   PubMedGoogle Scholar
• Olsson E, Ingman P, Ahmed B, Kalvemark Sporrong S. Pharmacist-patient communication in Swedish community pharmacies. Res Social Adm Pharm 2014;10(1):149-55
   PubMedGoogle Scholar
• Martin A, Godman B, Miranda J, et al. Measures to improve angiotensin receptor blocker prescribing efficiency in the UK: findings and implications. J Comp Eff Res 2014;3(1):41-51
   PubMed Web of Science ®Google Scholar
• Godman B, Bishop I, Finlayson AE, et al. Reforms and initiatives in Scotland in recent years to encourage the prescribing of generic drugs, their influence and implications for other countries. Expert Rev Pharmacoecon Outcomes Res 2013;13(4):469-82
   PubMed Web of Science ®Google Scholar
• Gray A. Medicines shortages-unpicking the evidence from a year in South Africa. Australas Med J 2014;7(5):208-12
   PubMedGoogle Scholar